Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
- GARAMYCIN®, INJEKTIONSVÄTSKA OCH INFUSIONSKONCENTRAT 80 MG/ML, SCHERING-PLOUGH AB
- SYNAGIS™, INJEKTIONSSUBSTANS I+II 100 MG, ABBOTT SCANDINAVIA AB
- BERIGLOBIN®, INJEKTIONSVÄTSKA, LÖSNING 160 MG/ML, AVENTIS BEHRING AB
- CLINDAMYCIN RATIOPHARM®, INJEKTIONS-/INFUSIONSVÄTSKA, LÖSNING 150 MG/ML, RATIOPHARM AB
Infectious Diseases Drug Data - A-Z (Svenska)
Drug Description
1 ml koncentrat till infusionsvätska, lösning 5 mg/ml innehåller: Amphotericin. B 5,0 mg, L-α-dimyristoylphosphatidylcholin. 3,4 mg, natr. et ammon. L-α-dimyristoyl-phosphatidylglycerol. 1,5 mg, natr. chlorid. 9,0 mg, aq. ad iniect. ad 1,0 ml.Presentation
Infusionskoncentrat 5 mg/mlIndications
Candidemi. Andra svåra invasiva svampinfektioner hos patienter som inte svarat på konventionell amfotericin B terapi eller annan systemisk antimykotisk terapi, eller där konventionell amfotericin B terapi inte kan användas på grund av njurtoxicitet eller nedsatt njurfunktion.Adult Dosage
Barn och vuxna: Normaldos 5 mg/kg en gång dagligen som långsam intravenös infusion under 2 timmar. Infusionshastigheten bör vara 2,5 mg/kg/timme. Full dos kan ges från första behandlingsdagen. När ABELCET ges för första gången bör en testdos ges före den första infusionen. Den första dosen beredes enligt instruktionerna och sedan ges en mängd motsvarande ca 1 mg amfotericin över 15 minuter. När denna mängd givits stoppas infusionen och patienten övervakas under 30 minuter. Om inga tecken på överkänslighet ses kan infusionen fortsättas.Behandlingstiden beror på infektionens natur och svårighetsgrad. Vanlig behandlingstid är 12 till 15 dagar.
Contra Indications
Överkänslighet mot ingående ämnen.Special Precautions
Hos patienter som står på annan samtidig behandling med nefrotoxiska läkemedel (inklusive ciklosporin i hög dos) är det speciellt viktigt att njurfunktionen kontrolleras noga. Hos patienter som står på samtidig behandling med zidovudin skall njurfunktion och blodbild följas noga.ABELCET kan ges under njurdialys eller hemofiltrering. Kalium- och magnesiumnivåer skall följas regelbundet.
Patienter med gravt nedsatt njurfunktion, nedsatt leverfunktion, splenektomerade patienter och diabetespatienter bör kontrolleras noga. Patienter med disseminerande candidemi och retinala exsudat är ej studerade.
Interactions
För konventionellt amfotericin B har interaktion med cytostatika, kortikosteroider, kortikotropin (ACTH), digitalisglykosider och muskelrelaxantia rapporterats.Adverse Reactions
De vanligaste biverkningarna är infusionrelaterad frossa och feber under de första 1—2 behandlingsdagarna.- Vanliga (>1/100) - Allmänna: Frossa, feber, tremor. GI: Illamående, kräkningar. Metabol.: Hypokalemi. Urogenital.: Ökat serumkreatinin.
- Mindre vanliga (1/100 - 1/1000) - Allmänna: Anafylaktoida reaktioner. Blod: Anemi, trombocytopeni, koagulationsrubbningar. Cirk.: Hypotension, hypertension, takykardi. Lever: Förhöjda leverenzymvärden. Luftvägar: Bronkospasm, dyspné.
Hos flertalet patienter med normal njurfunktion som ej tidigare behandlats med konventionellt amfotericin B förblev njurfunktionen stabil. Hos patienter som ställts om till ABELCET på grund av att de utvecklat nedsatt njurfunktion under behandling med konventionellt amfotericin B, har njurfunktionen i allmänhet normaliserats eller avsevärt förbättrats.
Manufacturer
Wyeth Lederle Nordiska ABAdvert for Healthcare Professionals Only
Related News
IlLLUMINATE trial of Incivek is published in NEJM Infectious Diseases Page
The New England Journal of Medicine (NEJM) published data from a Phase III study of Incivek(telaprevir) tablets in people with genotype 1 chronic Hepatitis C who were new to treatment. In ILLUMINATE, Incivek was given for the first 12 weeks in combination with pegylated-interferon and ribavirin. Nearly two-thirds of patients responded early to Incivek combination treatment (measured by having undetectable hepatitis C virus at weeks 4 and 12 of treatment) and were randomly assigned to receive an additional 12 weeks or 36 weeks of treatment with pegylated-interferon and ribavirin alone. Similarly high rates of sustained viral response (SVR, or viral cure) were achieved by people in both treatment groups. Rash and anemia were the most common side effects reported with Incivek in this study and each led to treatment discontinuation of all medicines in about 1 percent of people during the Incivek treatment phase. Data from ILLUMINATE are published in the September 15, 2011 issue of NEJM.
Incivek treatment still effective when course is half as long in treatment of Hepatitis C genotype 1 Infectious Diseases Page
A Phase III study (ADVANCE) of Incivek (telaprevir) tablets in patients with genotype 1 chronic Hepatitis C published in The New England Journal of Medicine (NEJM) reveals that a 24-week treatment course that adds Incivek to peginterferon alfa and ribavirin is just as effective as a 48-week regimen for many patients. Shortening the duration of treatment reduces a patient's exposure to side effects including rash and anemia.see Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection September 15, 2011Sherman K.E., Flamm S.L., Afdhal N.H., et al.N Engl J Med 2011; 365:1014 - 1024.
Vibativ is EU approved for nosocomial pneumonia caused by MNSA Infectious Diseases Page
Astellas and Theravance have received marketing authorisation from the European Commission for Vibativ (telavancin hydrochloride) for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).Its labelling will include its use in the treatment of adults with nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable. In the US and Canada, the drug was approved in 2009 for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of certain Gram-positive microorganisms, including Staphylococcus aureus ,including methicillin-susceptible and-resistant isolates but is not approved in these territories for the pneumonia indication. Vibativ is not yet available in Europe for use with skin such infections as are approved in the USA.
More News
